E
Algernon Pharmaceuticals Inc.
AGN
CNSX
E
Sell
3/15/2024Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to E+ from E on 3/15/2024 due to an increase in the volatility index.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to E+ from E on 3/15/2024 due to an increase in the volatility index.
E
Sell
2/29/2024Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E from E+ on 2/29/2024 due to a decline in the volatility index.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E from E+ on 2/29/2024 due to a decline in the volatility index.
E
Sell
2/14/2024Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to E+ from E on 2/14/2024 due to an increase in the volatility index.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to E+ from E on 2/14/2024 due to an increase in the volatility index.
E
Sell
1/29/2024Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E from E+ on 1/29/2024 due to a decline in the solvency index and volatility index. The quick ratio declined from 0.08 to 0.03.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E from E+ on 1/29/2024 due to a decline in the solvency index and volatility index. The quick ratio declined from 0.08 to 0.03.
E
Sell
1/24/2024Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to E+ from E on 1/24/2024 due to a large increase in the growth index and volatility index. Operating cash flow increased 20.46% from -$540.2 to -$429.7, earnings per share increased from -$0.0748 to -$0.0625, and EBIT increased 8.89% from -$783.2 to -$713.6.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to E+ from E on 1/24/2024 due to a large increase in the growth index and volatility index. Operating cash flow increased 20.46% from -$540.2 to -$429.7, earnings per share increased from -$0.0748 to -$0.0625, and EBIT increased 8.89% from -$783.2 to -$713.6.
E
Sell
12/11/2023Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E from E+ on 12/11/2023 due to a decline in the volatility index.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E from E+ on 12/11/2023 due to a decline in the volatility index.
E
Sell
11/24/2023Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to E+ from E on 11/24/2023 due to an increase in the volatility index.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to E+ from E on 11/24/2023 due to an increase in the volatility index.
E
Sell
11/6/2023Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E from E+ on 11/6/2023 due to a decline in the volatility index and growth index.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E from E+ on 11/6/2023 due to a decline in the volatility index and growth index.
E
Sell
10/20/2023Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to E+ from E on 10/20/2023 due to an increase in the volatility index.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to E+ from E on 10/20/2023 due to an increase in the volatility index.
E
Sell
10/2/2023Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E from E+ on 10/2/2023 due to a decline in the volatility index.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E from E+ on 10/2/2023 due to a decline in the volatility index.
E
Sell
9/15/2023Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to E+ from E on 9/15/2023 due to an increase in the volatility index.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to E+ from E on 9/15/2023 due to an increase in the volatility index.
E
Sell
8/30/2023Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E from E+ on 8/30/2023 due to a large decline in the growth index, solvency index and volatility index. Operating cash flow declined 65.55% from -$326.3 to -$540.2.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E from E+ on 8/30/2023 due to a large decline in the growth index, solvency index and volatility index. Operating cash flow declined 65.55% from -$326.3 to -$540.2.
E
Sell
3/14/2023Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and total return index.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and total return index.
D
Sell
2/24/2023Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 2/24/2023 due to a decline in the volatility index and total return index.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 2/24/2023 due to a decline in the volatility index and total return index.
D
Sell
2/9/2023Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and total return index.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and total return index.
D
Sell
2/2/2023Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from E+ on 2/2/2023 due to a major increase in the growth index and volatility index. Operating cash flow increased 47.55% from -$1.14M to -$598.7, earnings per share increased from -$0.892 to -$0.5863, and EBIT increased 19.29% from -$1.67M to -$1.35M.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from E+ on 2/2/2023 due to a major increase in the growth index and volatility index. Operating cash flow increased 47.55% from -$1.14M to -$598.7, earnings per share increased from -$0.892 to -$0.5863, and EBIT increased 19.29% from -$1.67M to -$1.35M.
E
Sell
12/20/2022Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E+ from D- on 12/20/2022 due to a decline in the total return index and volatility index.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E+ from D- on 12/20/2022 due to a decline in the total return index and volatility index.
D
Sell
11/28/2022Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 11/28/2022 due to a large decline in the growth index, volatility index and solvency index. EBIT declined 185.21% from -$586.2 to -$1.67M, earnings per share declined from -$0.3758 to -$0.8925, and operating cash flow declined 56.12% from -$731.6 to -$1.14M.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 11/28/2022 due to a large decline in the growth index, volatility index and solvency index. EBIT declined 185.21% from -$586.2 to -$1.67M, earnings per share declined from -$0.3758 to -$0.8925, and operating cash flow declined 56.12% from -$731.6 to -$1.14M.
D
Sell
5/16/2022Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 5/16/2022 due to an increase in the total return index.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 5/16/2022 due to an increase in the total return index.
D
Sell
5/1/2022Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 5/1/2022 due to a decline in the solvency index. The quick ratio declined from 4.83 to 1.59.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 5/1/2022 due to a decline in the solvency index. The quick ratio declined from 4.83 to 1.59.
D
Sell
4/25/2022Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 4/25/2022 due to an increase in the volatility index and total return index.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 4/25/2022 due to an increase in the volatility index and total return index.
D
Sell
1/26/2022Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 1/26/2022 due to a decline in the volatility index, total return index and valuation index.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 1/26/2022 due to a decline in the volatility index, total return index and valuation index.
D
Sell
1/7/2022Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 1/7/2022 due to an increase in the volatility index.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 1/7/2022 due to an increase in the volatility index.
D
Sell
12/20/2021Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 12/20/2021 due to a decline in the total return index and volatility index.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 12/20/2021 due to a decline in the total return index and volatility index.
D
Sell
11/29/2021Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 11/29/2021 due to a noticeable increase in the growth index. Earnings per share increased from -$0.8108 to -$0.1152, EBIT increased 67.93% from -$1.33M to -$425, and operating cash flow increased 55.07% from -$1.46M to -$654.3.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 11/29/2021 due to a noticeable increase in the growth index. Earnings per share increased from -$0.8108 to -$0.1152, EBIT increased 67.93% from -$1.33M to -$425, and operating cash flow increased 55.07% from -$1.46M to -$654.3.
D
Sell
11/3/2021Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 11/3/2021 due to a decline in the volatility index, total return index and growth index.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 11/3/2021 due to a decline in the volatility index, total return index and growth index.
D
Sell
7/30/2021Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 7/30/2021 due to a noticeable increase in the growth index, solvency index and valuation index. Earnings per share increased from -$0.013 to -$0.0081, and EBIT increased 27.25% from -$1.82M to -$1.33M.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 7/30/2021 due to a noticeable increase in the growth index, solvency index and valuation index. Earnings per share increased from -$0.013 to -$0.0081, and EBIT increased 27.25% from -$1.82M to -$1.33M.
D
Sell
5/19/2021Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 5/19/2021 due to a noticeable decline in the growth index and total return index.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 5/19/2021 due to a noticeable decline in the growth index and total return index.
D
Sell
5/18/2020Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 5/18/2020 due to an increase in the total return index and valuation index.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 5/18/2020 due to an increase in the total return index and valuation index.
D
Sell
5/1/2020Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 5/1/2020 due to a large decline in the growth index, valuation index and efficiency index. Net income declined 375.04% from -$125.8 to -$597.6, earnings per share declined from -$0.0023 to -$0.0081, and EBIT declined 240.65% from -$173.2 to -$590.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 5/1/2020 due to a large decline in the growth index, valuation index and efficiency index. Net income declined 375.04% from -$125.8 to -$597.6, earnings per share declined from -$0.0023 to -$0.0081, and EBIT declined 240.65% from -$173.2 to -$590.
D
Sell
3/5/2020Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 3/5/2020 due to an increase in the total return index and volatility index.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 3/5/2020 due to an increase in the total return index and volatility index.
D
Sell
2/19/2020Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 2/19/2020 due to a decline in the volatility index.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 2/19/2020 due to a decline in the volatility index.
D
Sell
2/4/2020Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 2/4/2020 due to a large increase in the growth index, efficiency index and solvency index. The quick ratio increased from 0.69 to 4.94, earnings per share increased from -$0.0068 to -$0.0023, and net income increased 60.88% from -$321.6 to -$125.8.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 2/4/2020 due to a large increase in the growth index, efficiency index and solvency index. The quick ratio increased from 0.69 to 4.94, earnings per share increased from -$0.0068 to -$0.0023, and net income increased 60.88% from -$321.6 to -$125.8.
D
Sell
7/30/2019Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 7/30/2019 due to a decline in the growth index, volatility index and efficiency index. Net income declined 18.8% from -$334.1 to -$396.9, earnings per share declined from -$0.0071 to -$0.0084, and EBIT declined 12.97% from -$325.3 to -$367.5.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 7/30/2019 due to a decline in the growth index, volatility index and efficiency index. Net income declined 18.8% from -$334.1 to -$396.9, earnings per share declined from -$0.0071 to -$0.0084, and EBIT declined 12.97% from -$325.3 to -$367.5.
D
Sell
3/7/2019Upgraded
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 3/7/2019 due to an increase in the valuation index and total return index.
Algernon Pharmaceuticals Inc. (AGN) was upgraded to D from D- on 3/7/2019 due to an increase in the valuation index and total return index.
D
Sell
2/20/2019Downgrade
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 2/20/2019 due to a decline in the valuation index and growth index.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to D- from D on 2/20/2019 due to a decline in the valuation index and growth index.
D
Sell
1/30/2019Upgraded
Breathtec Biomedical, Inc. (BTH) was upgraded to D from D- on 1/30/2019 due to an increase in the valuation index, growth index and volatility index.
Breathtec Biomedical, Inc. (BTH) was upgraded to D from D- on 1/30/2019 due to an increase in the valuation index, growth index and volatility index.
D
Sell
11/29/2018Upgraded
Breathtec Biomedical, Inc. (BTH) was upgraded to D- from E+ on 11/29/2018 due to an increase in the volatility index.
Breathtec Biomedical, Inc. (BTH) was upgraded to D- from E+ on 11/29/2018 due to an increase in the volatility index.
E
Sell
10/8/2018Downgrade
Breathtec Biomedical, Inc. (BTH) was downgraded to E+ from D- on 10/8/2018 due to a major decline in the growth index, total return index and volatility index. EBIT declined 173.52% from -$109.9 to -$300.6, earnings per share declined from -$0.0023 to -$0.0054, and operating cash flow declined 33.39% from -$112.3 to -$149.8.
Breathtec Biomedical, Inc. (BTH) was downgraded to E+ from D- on 10/8/2018 due to a major decline in the growth index, total return index and volatility index. EBIT declined 173.52% from -$109.9 to -$300.6, earnings per share declined from -$0.0023 to -$0.0054, and operating cash flow declined 33.39% from -$112.3 to -$149.8.
D
Sell
2/1/2018Upgraded
Breathtec Biomedical, Inc. (BTH) was upgraded to D- from E on 2/1/2018 due to a substantial increase in the total return index, growth index and volatility index. Operating cash flow increased 51.8% from -$286.3 to -$138, earnings per share increased from -$0.0041 to -$0.0028, and EBIT increased 31.6% from -$220.6 to -$150.9.
Breathtec Biomedical, Inc. (BTH) was upgraded to D- from E on 2/1/2018 due to a substantial increase in the total return index, growth index and volatility index. Operating cash flow increased 51.8% from -$286.3 to -$138, earnings per share increased from -$0.0041 to -$0.0028, and EBIT increased 31.6% from -$220.6 to -$150.9.
E
Sell
11/1/2017Upgraded
Breathtec Biomedical, Inc. (BTH) was upgraded to E from E- on 11/1/2017 due to an increase in the valuation index and total return index.
Breathtec Biomedical, Inc. (BTH) was upgraded to E from E- on 11/1/2017 due to an increase in the valuation index and total return index.
E
Sell
7/24/2017None
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E- from U on 07/24/2017.
Algernon Pharmaceuticals Inc. (AGN) was downgraded to E- from U on 07/24/2017.
